- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02314195
Music Therapy in Obsessive Compulsive Disorder
December 10, 2014 updated by: Shahrzad Shirani, Islamic Azad University, Marvdasht
A Randomized Clinical Trial of Music Therapy as an Adjunct to Standard Treatment for Obsessive Compulsive Disorder and Co-morbid Anxiety and Depression in Iran
Previous studies have highlighted the potential therapeutic benefits of receptive individual music therapy as an adjunct to standard care, in a variety of psychiatric ailments including mood and anxiety disorders.
However, the role of music in the treatment of obsessive compulsive disorder have not been investigated to date.
The present study therefore aimed to investigate the efficacy of music therapy as an adjunct to standard treatment, on obsessions in patients with treatment-naïve OCD.
Moreover, given the fact that a significant proportion of patients with OCD have other comorbid mood or anxiety disorders, the question of whether therapeutic benefits of music could be expanded to also affect concurrent depressive and anxiety symptoms was explored.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
30
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Esfahan, Iran, Islamic Republic of, 56465201
- Shariati Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- were at least 18 years or older;
- had axis I diagnosis of OCD according to the criteria delineated by the diagnostic and statistical manual of mental disorders - fourth edition diagnosed by an experienced psychiatrist
- had not received treatment previously for the disorder
- agreed to partake in the study
Exclusion Criteria:
- refused to partake in the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Standard treatment + music therapy
Selective serotonin re-uptake inhibitor plus cognitive behavioral therapy.
Music therapy encompassing 12 half-hour sessions of therapist-supervised receptive music therapy scheduled over four weeks
|
A medication of selective serotonin re-uptake inhibitor (SSRI) family, Behavioral.
The type and dosage of the medication was decided by the treating psychiatrist.
Other Names:
Cognitive Behavioral Therapy for obsessive compulsive disorder carried out by a psychologist.
Other Names:
12 sessions of 30-minute individual-based receptive music therapy, supervised by the treating psychiatrist.
Other Names:
|
Active Comparator: Standard treatment only
Selective serotonin re-uptake inhibitor plus cognitive behavioral therapy.
|
A medication of selective serotonin re-uptake inhibitor (SSRI) family, Behavioral.
The type and dosage of the medication was decided by the treating psychiatrist.
Other Names:
Cognitive Behavioral Therapy for obsessive compulsive disorder carried out by a psychologist.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Obsession (Maudsley Obsessive-Compulsive Inventory)
Time Frame: 1 month
|
Post-intervention scores on Maudsley Obsessive-Compulsive Inventory
|
1 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Obsession subtype (Maudsley Obsessive-Compulsive Inventory sub-types)
Time Frame: 1 month
|
Post-intervention scores on Maudsley Obsessive-Compulsive Inventory sub-types
|
1 month
|
Anxiety symptoms (Beck Anxiety Inventory)
Time Frame: 1 month
|
Post-intervention scores on Beck Anxiety Inventory
|
1 month
|
Depressive symptoms (Beck Depression Inventory - Short Form)
Time Frame: 1 month
|
Post-intervention scores on Beck Depression Inventory - Short Form
|
1 month
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2014
Primary Completion (Actual)
June 1, 2014
Study Completion (Actual)
August 1, 2014
Study Registration Dates
First Submitted
November 27, 2014
First Submitted That Met QC Criteria
December 10, 2014
First Posted (Estimate)
December 11, 2014
Study Record Updates
Last Update Posted (Estimate)
December 11, 2014
Last Update Submitted That Met QC Criteria
December 10, 2014
Last Verified
December 1, 2014
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Mental Disorders
- Pathologic Processes
- Personality Disorders
- Depression
- Disease
- Compulsive Personality Disorder
- Obsessive-Compulsive Disorder
- Anxiety Disorders
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Serotonin Agents
- Serotonin Receptor Agonists
- Serotonin
- Serotonin Uptake Inhibitors
Other Study ID Numbers
- 2172719
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
ProgenaBiomeRecruitingDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
University of California, San FranciscoRecruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
University GhentUniversiteit Antwerpen; Janssen-Cilag Ltd.RecruitingDepression Moderate | Depression Severe | Depression MildBelgium
-
Baylor College of MedicineUniversity of TexasRecruitingDepression | Depression Moderate | Depression Severe | Suicide and Self-harm | Depression in Adolescence | Depression MildUnited States
-
University of Cape TownNational Institute of Mental Health (NIMH)CompletedPostpartum Depression | Clinical Depression | Moderate DepressionSouth Africa
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; National Institute of Mental...CompletedMajor Depressive Disorder | Treatment Resistant Depression | Treatment-Refractory Depression | Late Life Depression | Geriatric DepressionUnited States, Canada
-
Northern Illinois UniversityUniversity Autonoma de Santo DomingoTerminatedDepression Moderate | Depression MildUnited States, Dominican Republic
-
Gerbera Therapeutics, Inc.Not yet recruitingPostpartum Depression | Depression, Postpartum | Postnatal Depression | Post-partum Depression | Post-Natal DepressionUnited States
-
Lawson Health Research InstituteTerminated
Clinical Trials on Selective serotonin re-uptake inhibitor
-
Baker Heart and Diabetes InstituteThe Alfred; Monash Medical Centre; Ballarat Health ServicesCompletedMajor Depressive DisorderAustralia
-
Ohio State UniversityWithdrawnDementia | Alzheimer Disease | Mild Cognitive ImpairmentUnited States
-
Eli Lilly and CompanyCompletedMajor Depressive Disorder (MDD)United States, Puerto Rico, Finland, Japan, Slovakia, Czechia, Croatia
-
Eli Lilly and CompanyCompletedMajor Depressive DisorderUnited States, Germany, Italy, Turkey, Russian Federation, Korea, Republic of, Greece, France, Croatia, Romania, Spain, Argentina, Puerto Rico, Belgium, Mexico, Slovakia
-
Eli Lilly and CompanyCompletedMajor Depressive DisorderUnited Kingdom, United States, Belgium, Austria, Australia, Germany, Sweden
-
Eli Lilly and CompanyCompletedMajor Depressive DisorderUnited States, South Africa, Poland, Ukraine, Japan, Russian Federation, Latvia
-
University of Sao PauloColumbia University; Amsterdam UMC, location VUmc; University of Stellenbosch; National...CompletedObsessive-Compulsive DisorderUnited States, Brazil, India, South Africa
-
Isfahan University of Medical SciencesCompletedLocal AnesthesiaIran, Islamic Republic of
-
US Department of Veterans AffairsOregon Health and Science UniversityCompletedDepression | Cancer | Palliative Care | Mental DisorderUnited States